NATCO Pharma Limited (NSE:NATCOPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 142.92B |
| Revenue (ttm) | 42.80B |
| Net Income (ttm) | 18.65B |
| Shares Out | 179.11M |
| EPS (ttm) | 104.13 |
| PE Ratio | 7.66 |
| Forward PE | 7.60 |
| Dividend | 6.00 (0.75%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 1,616,820 |
| Average Volume | 1,514,859 |
| Open | 792.00 |
| Previous Close | 793.15 |
| Day's Range | 778.30 - 816.00 |
| 52-Week Range | 778.30 - 1,639.00 |
| Beta | 0.55 |
| RSI | 21.19 |
| Earnings Date | Feb 11, 2025 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph... [Read more]
Financial Performance
In 2023, NATCO Pharma's revenue was 40.02 billion, an increase of 47.76% compared to the previous year's 27.09 billion. Earnings were 13.88 billion, an increase of 94.09%.
Financial StatementsNews
Stocks hitting 52-week low today, February 20: Natco Pharma, VIP Industries, Birlasoft and more
The Indian equity markets continued their downward trend for the third consecutive session on February 20, 2024, with both the Sensex and Nifty 50 closing lower. The BSE Sensex dropped 203.22 points (...
Stocks hitting 52-week low today, February 19: Natco Pharma, Godrej Consumer, Trident, BEML and more
The Indian stock market experienced a volatile session on February 19, 2024, with benchmark indices closing marginally lower. The BSE Sensex ended at 75,939.18, down by 28.21 points (-0.04%), while th...
Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with ...
Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Plans
Natco Pharma shares drop 30% in 2 days following poor Q3 results
Shares of Natco Pharma have witnessed a sharp 30% decline in just two days following the release of its weak Q3 FY25 earnings. Today, As of 9:37 AM, the shares were trading 8.85% lower at Rs 888.80. T...
Top market losers: Natco Pharma plunges 18.65%, Vijaya Diagnostic down 7.20%, Godfrey Phillips slips 4.18%
The Indian stock market witnessed significant declines in several stocks as selling pressure weighed on select counters. Natco Pharma emerged as the biggest loser, plunging 18.65% to ₹991.45. The stoc...
Natco Pharma shares drop 16% as Q3 revenue falls 37% YoY
Natco Pharma Ltd. witnessed a sharp decline of 16% in its stock price following a disappointing performance in the third quarter of FY25. The pharmaceutical company’s consolidated net profit fell to R...
Natco Pharma Q3 FY25 Results: Revenue down 37.4% to Rs 475 crore, Net Profit declines 37.8% YoY
Natco Pharma Ltd. has reported a significant decline in its financial performance for Q3 FY25, with a sharp drop in revenue, net profit, and EBITDA margins. Key Financial Highlights (Q3 FY25 vs Q3 FY2...
Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets
Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) ...
NATCO Pharma secures final FDA approval for Generic Bosentan TFOS 32mg
NATCO Pharma Limited has received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer®...
Natco Pharma secures USFDA approval for generic Everolimus tablets, eyes $112 million market
Natco Pharma Limited has announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) in 2mg, 3mg, and 5mg strengths....
Healthcare Stocks: Yatharth Hospital down 8.73%, Suven Pharma up 2%, AstraZeneca up 1.22%
Healthcare stocks witnessed mixed performance in the trading session, reflecting varied investor sentiment across the sector. Below is a detailed analysis of major gainers and losers: Top Gainers Suve...
Natco Pharma reports 90.8% YoY export growth in November
Natco Pharma has delivered remarkable export growth for November 2024, marking a standout performance among API and formulation companies. The company recorded a significant 90.8% year-over-year (YoY)...
Natco Pharma shares rise after selling Telangana land for Rs 115.6 crore
Shares of Natco Pharma edged up 1.01% to ₹1,364.90 in early trading today, following the company’s announcement of selling a 14.38-acre land parcel in Telangana for ₹115.57 crore. The transaction incl...
Natco Pharma sells Telangana land for ₹115.57 crore
Natco Pharma Limited has announced the sale of a 14.38-acre land parcel, equivalent to 72,358 square yards, located at Mekaguda Gram Panchayat, Nandigama Mandal, Ranga Reddy District, Telangana.
Natco Pharma submits ANDA for Risdiplam for oral solution
Natco Pharma has announced its submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to the U.S. FDA for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL Ora...
Natco Pharma Q2 FY24-25 Results: Revenue rises 32.1% YoY to ₹1,371 crore, profit surges 81.2% to ₹676.5 crore
Natco Pharma Limited has reported strong financial results for the second quarter ended September 30, 2024, showcasing significant growth in both revenue and profitability. Quarterly Financial Highlig...
Natco Pharma Q2 FY25 results: Stock surge over 2% ahead of result announcement
Shares of Natco Pharma saw a notable rise of over 2%, reaching an intraday high of ₹1,435.40, as investors eagerly anticipate the company’s upcoming Q2 FY25 results. The stock opened at ₹1,402.00 and ...
Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings
A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...
Health groups join patent war over spinal muscular atrophy drug
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Na...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Top Morning Losers Today: Home First, RITES, ICICI Securities, Natco Pharma, Thermax lead declines [Oct 10]
Several stocks are facing downward pressure in the morning session as of 10:41 AM. Here are the top losers: Home First Finance (HOMEFIRST): The stock fell by 4.90%, trading at ₹1,245.25, down ₹64.10. ...
Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%
As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...
NATCO Pharma shares surge 3% after announcing settlement in U.S. patent litigation
NATCO Pharma shares jumped more than 3% in morning trade after the company announced that Mylan Pharmaceuticals Inc. and Novo Nordisk had settled a U.S. patent litigation concerning developing a gener...
NATCO Pharma announces settlement in U.S. patent litigation for generic Ozempic
NATCO Pharma Limited has announced that Mylan Pharmaceuticals Inc. and Novo Nordisk have settled a U.S. patent litigation concerning the development of a generic version of Ozempic (Semaglutide). The ...